Unexpected responses to EGFR inhibition in NSCLC.

about

Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene.

P2860

Q33618824-849F3FCE-23EF-4291-AA10-773CDA60A5F8

P2860

Unexpected responses to EGFR inhibition in NSCLC.

Item

http://www.wikidata.org/entity/Q36378879

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Unexpected responses to EGFR inhibition in NSCLC.

@ast

Unexpected responses to EGFR inhibition in NSCLC.

@en

type

Item

label

Unexpected responses to EGFR inhibition in NSCLC.

@ast

Unexpected responses to EGFR inhibition in NSCLC.

@en

prefLabel

Unexpected responses to EGFR inhibition in NSCLC.

@ast

Unexpected responses to EGFR inhibition in NSCLC.

@en

P1476

Unexpected responses to EGFR inhibition in NSCLC.

@en

P2093

Adele Valentini

http://www.w3.org/2001/XMLSchema#string

Claudio Valizia

http://www.w3.org/2001/XMLSchema#string

Francesco Valentino

http://www.w3.org/2001/XMLSchema#string

Giulia M Stella

http://www.w3.org/2001/XMLSchema#string

Giulio Orlandoni

http://www.w3.org/2001/XMLSchema#string

Patrizia Morbini

http://www.w3.org/2001/XMLSchema#string

Roberto Dore

http://www.w3.org/2001/XMLSchema#string

Sara Colombo

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.

Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

MET mutations in cancers of unknown primary origin (CUPs).

Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.

P304

32-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.RMCR.2015.06.006

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Zorzetto

Simona Inghilleri

P577

2015-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279313259

http://www.w3.org/2001/XMLSchema#string

P698

26744648

http://www.w3.org/2001/XMLSchema#string

P932

4681892

http://www.w3.org/2001/XMLSchema#string

Unexpected responses to EGFR inhibition in NSCLC.

about

P2860

P2860

Unexpected responses to EGFR inhibition in NSCLC.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932